mRNA Engineering of Allogeneic Mesenchymal Stem Cells Enables Coordinated Delivery of T Cell Engagers and Immunotherapeutic Cues

Researchers used mRNA engineering to create an off-the-shelf immunotherapy that they termed DC-25. DC-25 consists of a mesenchymal stem cell armed with three designed mRNA constructs.